Diabetes-mediated middle cerebral artery remodeling is restored by linagliptin

Interaction with the vascular smooth muscle cell endothelin system

Abdul Yasir, Trevor Hardigan, Adviye Ergul

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction Endothelin-1 (ET-1) mediates cerebrovascular remodeling in vascular smooth muscle layer of the middle cerebral arteries (MCA) in type-2 diabetic Goto-Kakizaki (GK) rats. While metformin, oral glucose lowering agent, prevent/restores vascular remodeling and reduce systemic and local ET-1 levels whether this effect was specific to metformin remained unknown. Our working hypotheses were 1) linagliptin, a DPP-IV inhibitor, can reverse diabetes-mediated cerebrovascular remodeling and this is associated with decreased ET-1, and 2) linagliptin prevents the high glucose induced increase in ET-1 and ET receptors in brain vascular smooth muscle cells (bVSMCs). Methods Diabetic and non-diabetic GK rats were treated with linagliptin (4 weeks). MCAs were fixed in buffered 4% paraformaldehyde and used for morphometry. Human bVSMCs incubated in normal glucose (5.5 mM)/high glucose (25 mM) conditions were treated with the linagliptin (100 nM; 24 h). ET-1 secretion and ET receptors were measured in media and cell lysate respectively. Immunostaining was performed for ET-A and ET-B receptor. ET receptors were also measured in cells treated with ET-1 (100 nM) and linagliptin. Results Linagliptin treatment regressed vascular remodeling of MCAs in diabetic animals but had no effect on blood glucose. bVSMCs in normal/high glucose condition did not show any significant difference in ET-1 secretion or ET-A and ET-B receptor expression. ET-1 treatment in high glucose condition significantly increased the ET-A receptors and this effect was inhibited by linagliptin. Conclusions Linagliptin is effective in reversing established pathological cerebrovascular remodeling associated with diabetes. Attenuation of the ET system could be a pleiotropic effect of linagliptin that provides vascular protection.

Original languageEnglish (US)
Pages (from-to)76-82
Number of pages7
JournalLife sciences
Volume159
DOIs
StatePublished - Aug 15 2016

Fingerprint

Endothelins
Middle Cerebral Artery
Medical problems
Vascular Smooth Muscle
Endothelin-1
Smooth Muscle Myocytes
Muscle
Cells
Glucose
Brain
Metformin
Rats
Endothelin-2
Linagliptin
Endothelin A Receptors
Blood Vessels
Blood Glucose
Animals

Keywords

  • Diabetes
  • Endothelin
  • Linagliptin and brain vascular smooth muscle cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Diabetes-mediated middle cerebral artery remodeling is restored by linagliptin : Interaction with the vascular smooth muscle cell endothelin system. / Yasir, Abdul; Hardigan, Trevor; Ergul, Adviye.

In: Life sciences, Vol. 159, 15.08.2016, p. 76-82.

Research output: Contribution to journalArticle

@article{e4786cce312a4f93afac911ee31d6ec4,
title = "Diabetes-mediated middle cerebral artery remodeling is restored by linagliptin: Interaction with the vascular smooth muscle cell endothelin system",
abstract = "Introduction Endothelin-1 (ET-1) mediates cerebrovascular remodeling in vascular smooth muscle layer of the middle cerebral arteries (MCA) in type-2 diabetic Goto-Kakizaki (GK) rats. While metformin, oral glucose lowering agent, prevent/restores vascular remodeling and reduce systemic and local ET-1 levels whether this effect was specific to metformin remained unknown. Our working hypotheses were 1) linagliptin, a DPP-IV inhibitor, can reverse diabetes-mediated cerebrovascular remodeling and this is associated with decreased ET-1, and 2) linagliptin prevents the high glucose induced increase in ET-1 and ET receptors in brain vascular smooth muscle cells (bVSMCs). Methods Diabetic and non-diabetic GK rats were treated with linagliptin (4 weeks). MCAs were fixed in buffered 4{\%} paraformaldehyde and used for morphometry. Human bVSMCs incubated in normal glucose (5.5 mM)/high glucose (25 mM) conditions were treated with the linagliptin (100 nM; 24 h). ET-1 secretion and ET receptors were measured in media and cell lysate respectively. Immunostaining was performed for ET-A and ET-B receptor. ET receptors were also measured in cells treated with ET-1 (100 nM) and linagliptin. Results Linagliptin treatment regressed vascular remodeling of MCAs in diabetic animals but had no effect on blood glucose. bVSMCs in normal/high glucose condition did not show any significant difference in ET-1 secretion or ET-A and ET-B receptor expression. ET-1 treatment in high glucose condition significantly increased the ET-A receptors and this effect was inhibited by linagliptin. Conclusions Linagliptin is effective in reversing established pathological cerebrovascular remodeling associated with diabetes. Attenuation of the ET system could be a pleiotropic effect of linagliptin that provides vascular protection.",
keywords = "Diabetes, Endothelin, Linagliptin and brain vascular smooth muscle cells",
author = "Abdul Yasir and Trevor Hardigan and Adviye Ergul",
year = "2016",
month = "8",
day = "15",
doi = "10.1016/j.lfs.2016.02.096",
language = "English (US)",
volume = "159",
pages = "76--82",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Diabetes-mediated middle cerebral artery remodeling is restored by linagliptin

T2 - Interaction with the vascular smooth muscle cell endothelin system

AU - Yasir, Abdul

AU - Hardigan, Trevor

AU - Ergul, Adviye

PY - 2016/8/15

Y1 - 2016/8/15

N2 - Introduction Endothelin-1 (ET-1) mediates cerebrovascular remodeling in vascular smooth muscle layer of the middle cerebral arteries (MCA) in type-2 diabetic Goto-Kakizaki (GK) rats. While metformin, oral glucose lowering agent, prevent/restores vascular remodeling and reduce systemic and local ET-1 levels whether this effect was specific to metformin remained unknown. Our working hypotheses were 1) linagliptin, a DPP-IV inhibitor, can reverse diabetes-mediated cerebrovascular remodeling and this is associated with decreased ET-1, and 2) linagliptin prevents the high glucose induced increase in ET-1 and ET receptors in brain vascular smooth muscle cells (bVSMCs). Methods Diabetic and non-diabetic GK rats were treated with linagliptin (4 weeks). MCAs were fixed in buffered 4% paraformaldehyde and used for morphometry. Human bVSMCs incubated in normal glucose (5.5 mM)/high glucose (25 mM) conditions were treated with the linagliptin (100 nM; 24 h). ET-1 secretion and ET receptors were measured in media and cell lysate respectively. Immunostaining was performed for ET-A and ET-B receptor. ET receptors were also measured in cells treated with ET-1 (100 nM) and linagliptin. Results Linagliptin treatment regressed vascular remodeling of MCAs in diabetic animals but had no effect on blood glucose. bVSMCs in normal/high glucose condition did not show any significant difference in ET-1 secretion or ET-A and ET-B receptor expression. ET-1 treatment in high glucose condition significantly increased the ET-A receptors and this effect was inhibited by linagliptin. Conclusions Linagliptin is effective in reversing established pathological cerebrovascular remodeling associated with diabetes. Attenuation of the ET system could be a pleiotropic effect of linagliptin that provides vascular protection.

AB - Introduction Endothelin-1 (ET-1) mediates cerebrovascular remodeling in vascular smooth muscle layer of the middle cerebral arteries (MCA) in type-2 diabetic Goto-Kakizaki (GK) rats. While metformin, oral glucose lowering agent, prevent/restores vascular remodeling and reduce systemic and local ET-1 levels whether this effect was specific to metformin remained unknown. Our working hypotheses were 1) linagliptin, a DPP-IV inhibitor, can reverse diabetes-mediated cerebrovascular remodeling and this is associated with decreased ET-1, and 2) linagliptin prevents the high glucose induced increase in ET-1 and ET receptors in brain vascular smooth muscle cells (bVSMCs). Methods Diabetic and non-diabetic GK rats were treated with linagliptin (4 weeks). MCAs were fixed in buffered 4% paraformaldehyde and used for morphometry. Human bVSMCs incubated in normal glucose (5.5 mM)/high glucose (25 mM) conditions were treated with the linagliptin (100 nM; 24 h). ET-1 secretion and ET receptors were measured in media and cell lysate respectively. Immunostaining was performed for ET-A and ET-B receptor. ET receptors were also measured in cells treated with ET-1 (100 nM) and linagliptin. Results Linagliptin treatment regressed vascular remodeling of MCAs in diabetic animals but had no effect on blood glucose. bVSMCs in normal/high glucose condition did not show any significant difference in ET-1 secretion or ET-A and ET-B receptor expression. ET-1 treatment in high glucose condition significantly increased the ET-A receptors and this effect was inhibited by linagliptin. Conclusions Linagliptin is effective in reversing established pathological cerebrovascular remodeling associated with diabetes. Attenuation of the ET system could be a pleiotropic effect of linagliptin that provides vascular protection.

KW - Diabetes

KW - Endothelin

KW - Linagliptin and brain vascular smooth muscle cells

UR - http://www.scopus.com/inward/record.url?scp=84959890689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959890689&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2016.02.096

DO - 10.1016/j.lfs.2016.02.096

M3 - Article

VL - 159

SP - 76

EP - 82

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

ER -